Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%

cryptocurrency 1 week ago
Flipboard
Takeda Pharmaceutical (NYSE: TAK) reveals fiscal year 2023 results & restructuring plan. Revenue up 5.9%, net profit down 54.6%. Expecting operating …
Read Entire Article